Nanologica AB - Asset Resilience Ratio
Nanologica AB (NICA) has an Asset Resilience Ratio of 1.14% as of September 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NICA net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Nanologica AB's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Nanologica AB total assets.
Liquid Assets Composition Over Time
This chart breaks down Nanologica AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Nanologica AB (NICA) financial obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr1.05 Million | 1.14% |
| Total Liquid Assets | Skr1.05 Million | 1.14% |
Asset Resilience Insights
- Limited Liquidity: Nanologica AB maintains only 1.14% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Nanologica AB Industry Peers by Asset Resilience Ratio
Compare Nanologica AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for Nanologica AB (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Nanologica AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | Skr-1.00K ≈ $-107.62 |
Skr143.10 Million ≈ $15.40 Million |
-0.73pp |
| 2021-12-31 | 0.73% | Skr714.00K ≈ $76.84K |
Skr98.32 Million ≈ $10.58 Million |
-0.38pp |
| 2020-12-31 | 1.10% | Skr1.61 Million ≈ $173.80K |
Skr146.34 Million ≈ $15.75 Million |
+1.10pp |
| 2019-12-31 | 0.00% | Skr1.00 ≈ $0.11 |
Skr42.29 Million ≈ $4.55 Million |
0.00pp |
| 2018-12-31 | 0.00% | Skr1.00 ≈ $0.11 |
Skr34.33 Million ≈ $3.69 Million |
-- |
About Nanologica AB
Nanologica AB (publ), a life science tools company, develops, manufactures, and sells nanoporous silica particles in China, India, Turkey, the United States, and internationally. The company offers NLAB Saga, a silica-based purification media for preparative chromatography that is developed for the purification of peptide drugs, such as insulin and GLP-1 analogues; NLAB Idun, an ion exchange prod… Read more